The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 25, 2014
Filed:
Sep. 05, 2008
Jane Spetzler, Brønshøj, DK;
Lauge Schäffer, Lyngby, DK;
Jesper Lau, Farum, DK;
Thomas Kruse, Herlev, DK;
Patrick William Garibay, Holte, DK;
Steffen Reedtz-runge, Frederiksberg, DK;
Henning Thøgersen, Farum, DK;
Ingrid Pettersson, Frederiksberg, DK;
Jane Spetzler, Brønshøj, DK;
Lauge Schäffer, Lyngby, DK;
Jesper Lau, Farum, DK;
Thomas Kruse, Herlev, DK;
Patrick William Garibay, Holte, DK;
Steffen Reedtz-Runge, Frederiksberg, DK;
Henning Thøgersen, Farum, DK;
Ingrid Pettersson, Frederiksberg, DK;
Novo Nordisk A/S, Bagsvaerd, DK;
Abstract
The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.